Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 percent in 2024 to 100 billion Danish kroner ($13.9 billion). Europe's most valuable company said its sales rose 25 percent to 290.4 billion Danish kroner, propelled by its popular injections. "We are [...]The post Weight-loss drugmaker Novo Nordisk's profit jumps 21% in 2024 appeared first on The Guardian Nigeria News - Nigeria and World News.
Related Articles
Don't miss out on breaking stories and in-depth articles.